Floatz logo

Cetuximab

Skin Toxicity

Sun Yat-sen Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Skin Toxicity cohort.

Asset / SponsorPhaseRating
Doxycycline
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2B
Irinotecan
Amgen
Phase 2B
PANITUMUMAB
Amgen
Phase 2B
Crisaborole
Sun Yat-sen University
Phase 2CCC
Triamcinalone
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Clindamycin
Memorial Sloan Kettering Cancer Center
Phase 2CCC

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →